Currently browsing: Webinars

The Canine-Kid Connection — SLIDE DECK

In this All-Member Webinar for November 2016, we provided an overview of the compelling case for studying and treating cancer in canine cancer patients – a model of spontaneously occurring disease - the underlying science, and its potential not only to help us better understand and treat pediatric cancer, but also to accelerate the pediatric cancer drug development process. CAC2 Member Ulrike Szalay of Canines -N-Kids explains:  "As we know too well, cancer is the #1 cause of disease-related death in children in most developed countries. At least 1 in 5 will die from their disease, while the vast majority [...] Read more

The Canine-Kid Connection — SLIDE DECK

In this All-Member Webinar for November 2016, we provided an overview of the compelling case for studying and treating cancer in canine cancer patients – a model of spontaneously occurring disease – the underlying science, and its potential not only to help us better understand and treat pediatric cancer, but also to accelerate the pediatric cancer drug development process. CAC2 Member Ulrike Szalay of Canines -N-Kids explains:  “As we know too well, cancer is the #1 cause of disease-related death in children in most developed countries. At least 1 in 5 will die from their disease, while the vast majority […]

Read more

The Blue Ribbon Panel Report and Pediatric Cancer

Earlier this year, as part of Vice President Biden’s Cancer Moonshot initiative, the White House established a Blue Ribbon Panel of experts to report on the current challenges and opportunities facing cancer research. In this CAC2 Research Interest Group webinar for September1 2016, CAC2 welcomed Blue Ribbon Panel members Dr. Peter Adamson (Chair of the Children's Oncology Group) and David Arons (CEO of the National Brain Tumor Society) in a discussion of the panel’s recently issued report and its implications for pediatric cancer. Read more

Basics of a Clinical Trial in Pediatrics: A Sponsor’s Perspective

In this All-Member and all-community webinar for August 2016, CAC2 welcomes Drs. Michael Trigg, Brigid Bradley-Garelik, and Greg Plautz from Bristol-Myers Squib, speaking on the clinical trial process. These three esteemed industry experts will provide an overview of the clinical trial process, particularly from an industry-sponsored trial perspective and cover topics such as clinical trial designs, different required FDA phases of drug development, data monitoring committees, general principles of pediatric trials and special considerations of pediatric trials, industry obligations to pediatrics and personalized medicine. This presentation was not recorded. Read more

Basics of a Clinical Trial in Pediatrics: A Sponsor’s Perspective

In this All-Member and all-community webinar for August 2016, CAC2 welcomes Drs. Michael Trigg, Brigid Bradley-Garelik, and Greg Plautz from Bristol-Myers Squib, speaking on the clinical trial process. These three esteemed industry experts will provide an overview of the clinical trial process, particularly from an industry-sponsored trial perspective and cover topics such as clinical trial designs, different required FDA phases of drug development, data monitoring committees, general principles of pediatric trials and special considerations of pediatric trials, industry obligations to pediatrics and personalized medicine. This presentation was not recorded.

Read more

Cavatica: The Promise of Big Data

In this CAC2 Research Interest Group webinar for July 2016, CAC2 welcomed host Dr. Adam Resnick of the Children's Hospital of Philadelphia, Dr. Javad Nazarian of Children's Nationwide Hospital, and CAC2 member Amanda Haddock (Dragon Masters Foundation) discussing the Cavatica platform and how it can bring pediatric cancer research in line with the adult initiatives. Dr. Reznick presented about Cavatica, an exciting new cloud-based environment for securely storing, sharing and analyzing large volumes of pediatric brain tumor genomics data.  Cavatica will, for the first time, allow doctors, researchers and data scientists unparalleled access to pediatric brain tumor genomic data paired with a [...] Read more

Non-Profit Driven Pediatric Oncology Drug Development

In this All-Member webinar for May 2016, CAC2 welcomed Dr. Cesare Spadoni, Chairman and Co-Founder of Accelerating Paediatric Oncology Drug Development. Parents and non-profit entities can play a strong role in driving drug development and thus accelerate the availability of more innovative drugs for children with cancer. But to do, so they must adopt new operating models and collaborate more effectively with other stakeholders. Read more

Non-Profit Driven Pediatric Oncology Drug Development

In this All-Member webinar for May 2016, CAC2 welcomed Dr. Cesare Spadoni, Chairman and Co-Founder of Accelerating Paediatric Oncology Drug Development.  Parents and non-profit entities can play a strong role in driving drug development and thus accelerate the availability of more innovative drugs for children with cancer. But to do, so they must adopt new operating models and collaborate more effectively with other stakeholders.   PUT_CHARACTERS_HERE

Read more

Epigenetics, Pharmacogenetics and Pharmacogenomics

In this CAC2 Research Interest Group monthly webinar, presented on April 13, 2016, we welcomed Dr. John Maris, Giulio D'Angio Endowed Professor of Pediatric Oncology at the Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania.  Dr. Maris shared with us the process of learning causations, mutations, and finding targets in childhood cancer. Read more

Landmark Lightings and Proclamations

In this All-Member webinar for February 2015, CAC2 welcomed presenters Tony Stoddard (Sophia's Fund) and Neal Rourke (International Individual Member). Tony and Neal presented an interactive webinar to encourage dialogue between our members about Landmark Lightings and Proclamations.  They shared their past successes and techniques to help our members reach awareness goals in their communities. Read more

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.